Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + gemcitabine + topotecan
- Development stage
- Unknown
- Lead developer
- Michigan State University
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of cisplatin, gemcitabine, and topotecan. This three-drug combination has been studied primarily for the treatment of advanced non-small cell lung cancer. Each component has a distinct mechanism of action: cisplatin crosslinks DNA, gemcitabine is a nucleoside analog that inhibits DNA synthesis, and topotecan is a topoisomerase I inhibitor.
02
Targets
DNA polymerase familyTOP1 (DNA Topoisomerase I)DNA
Beyond the preview
Go deeper on cisplatin + gemcitabine + topotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + gemcitabine + topotecan.